Research Articles | Page 9 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study Oct 2023 Leukemia Aplastic Anemia
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Jan 2021 Leukemia Myelodysplastic Syndromes (MDS)
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) Jul 2020 Leukemia Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index Sep 2020 Leukemia Myelodysplastic Syndromes (MDS)
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia Mar 2021 Leukemia Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Rethinking clinical trial endpoints in myelodysplastic syndromes. Jan 2019 Leukemia Myelodysplastic Syndromes (MDS)
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Jan 2019 Leuk Lymphoma. Myelodysplastic Syndromes (MDS)
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial Jul 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study Jan 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)